Medicare IRMAA 2026: The $202.90 Premium Surge and the Advisor Playbook for Surcharge Avoidance

The Centers for Medicare & Medicaid Services confirmed in late 2025 that the standard Medicare Part B premium would rise 9.7% to $202.90 per month beginning January 1, 2026 — a jump of $17.90 from the prior year’s $185.00 baseline. For the average Social Security recipient, whose 2026 COLA was 2.8%, that premium increase consumed nearly one-third of the benefit enhancement before the first dollar reached their bank account. The net income impact on a retiree collecting $2,000 per month in Social Security: a net gain of just $37.10 after Medicare withholding.

That math — COLA underperforming premium inflation by more than 6 percentage points — is not a rounding error. It is a structural planning problem, and it arrives with a complexity layer that many retirees and their advisors still underestimate: the Income-Related Monthly Adjustment Amount, known as IRMAA.

What IRMAA Is — and Why It Hits Harder Than the Headline Premium

IRMAA is a Medicare surcharge applied to Part B and Part D premiums for beneficiaries above certain income thresholds. The 2026 brackets are based on 2024 modified adjusted gross income (MAGI), creating what practitioners call the “two-year lookback” — a planning window that cuts both ways.

For 2026, IRMAA begins at MAGI above $109,000 (single) or $218,000 (married filing jointly). There are five surcharge tiers:

For Part D, surcharges range from $14.50 to $91.00 per month, based on the same income brackets.

A married couple with combined MAGI of $225,000 — well within the range of a retired physician, small business owner, or dual-income professional household — faces $2,088 in annual IRMAA surcharges per person. At the household level: $4,176 in additional Medicare costs that did not appear on any budget worksheet before 2024.

The Two-Year Lookback: Planning Windows That Advisors Cannot Afford to Miss

The IRMAA mechanism uses a two-year lookback: the 2026 surcharge is based on 2024 MAGI; the 2028 surcharge will be based on 2026 MAGI. This creates a dual planning imperative.

Backward-looking: Clients who experienced elevated income in 2024 — a business sale, large IRA distribution, lump-sum pension, or capital gain event — are paying for it now in 2026 premiums. If the income spike was a one-time event, an appeal may apply.

Forward-looking: Decisions made today about 2026 income — how much to Roth convert, whether to harvest capital gains, when to take RMDs — will directly determine 2028 Medicare premiums. That two-year visibility is a genuine planning lever.

The Kiplinger Medicare planning team describes this as “the most actionable, yet most commonly neglected, dimension of retirement income planning.” Financial advisors who ignore IRMAA in their annual client reviews are leaving a measurable and avoidable cost on the table.

The Advisor Playbook: Four Strategies That Work in 2026

Strategy 1: Qualified Charitable Distributions (QCDs) — The Most Powerful Tool

For clients aged 70½ or older, QCDs allow a direct transfer of up to $111,000 per person in 2026 from a traditional IRA to a qualified charity. The critical advantage: QCDs count toward the Required Minimum Distribution but are excluded from MAGI entirely.

A client with a $1.5 million IRA and an RMD of $62,000 who would otherwise be pushed into the second IRMAA tier ($136,001–$163,000 MAGI) can use a $25,000 QCD to bring MAGI back below the $136,000 threshold — saving $1,044 in annual IRMAA surcharges and reducing federal taxable income simultaneously.

Morningstar’s retirement research team flagged QCDs as the “most underutilized tax planning tool available to retirees over 70½” in its 2025 retirement report, noting that fewer than 15% of eligible IRA holders used them in 2024. For advisors with clients in this age group, this gap represents a high-value planning conversation.

Strategy 2: Staged Roth Conversions Timed to IRMAA Tier Boundaries

Roth conversions increase current-year MAGI — which determines IRMAA two years forward. But executed strategically, they reduce future RMDs, which reduces future MAGI, which reduces future IRMAA surcharges. The net present value of that trade-off is often substantially positive, particularly for clients in their early 60s who haven’t yet enrolled in Medicare.

The critical discipline: convert up to — but not over — an IRMAA tier boundary. A client with $100,000 in 2026 MAGI has $9,000 of “room” before hitting the $109,000 first IRMAA tier. Converting that $9,000 from a traditional to Roth IRA costs nothing in IRMAA terms for 2028. Converting $10,000 triggers $1,044 in additional annual surcharges beginning in 2028.

This bracket-edge precision is why the Roth conversion strategy for Medicare-enrolled clients cannot be run on autopilot. As detailed in our earlier analysis of the OBBBA Roth conversion environment, the 2026 tax landscape — with potentially permanent current-rate brackets under OBBBA — further elevates the value of conversion discipline.

Strategy 3: Coordinate Distributions and Capital Gains Across Accounts

Large one-time income events are the primary cause of IRMAA surcharge surprises two years later. The sale of a second home, an inherited IRA that must be depleted under the 10-year rule, or a business sale — all of these create MAGI spikes that show up in Medicare premiums with a two-year delay.

The planning intervention: spread distributions over multiple tax years wherever possible. An inherited IRA required to be distributed by 2031 under the SECURE Act 10-year rule does not have to be taken in equal annual installments. An advisor can model the IRMAA impact of front-loading vs. back-loading distributions and identify the year-by-year strategy that minimizes total Medicare cost.

For capital gains: consider whether gains can be harvested across two tax years rather than one. A gain of $100,000 taken entirely in 2026 may push MAGI into the third IRMAA tier for 2028, while splitting $50,000 into 2026 and $50,000 into 2027 may keep the client in the first tier in both years — saving over $4,000 in cumulative IRMAA costs.

Strategy 4: The SSA-44 Appeal for Life-Changing Events

If a client’s 2024 MAGI was elevated due to a specific life-changing event, they may qualify for an immediate IRMAA reduction using Form SSA-44 (Medicare Income-Related Monthly Adjustment Amount — Life-Changing Event).

Qualifying events include: marriage, divorce, death of a spouse, work stoppage or reduction, loss of income-producing property, and reduction in pension income. The form allows the Social Security Administration to base the IRMAA determination on more recent income data rather than the two-year lookback default.

Advisors should flag SSA-44 for any client who experienced an income drop of more than $20,000 in 2025 due to a qualifying event. CMS data suggests fewer than 8% of IRMAA-affected beneficiaries who would qualify for an appeal actually file one — representing a significant advisory gap.

The Part D Dimension: Prescription Drug Costs in 2026

The Inflation Reduction Act’s $2,000 out-of-pocket cap on Part D prescription costs — effective in 2025 — has been indexed to approximately $2,100 in 2026. For clients on expensive specialty medications, that cap is genuinely valuable and should be factored into any plan comparison during Medicare open enrollment.

Separately, CMS negotiated prices for 10 high-cost drugs took effect January 1, 2026. Eliquis, Jardiance, and Xarelto are among the drugs subject to new negotiated pricing. For clients on these medications, the net cost reduction is meaningful — but it does not substitute for IRMAA planning, which affects the premium layer before drug costs even enter the calculation.

GLP-1 medications — Ozempic, Wegovy, Mounjaro — are now available at a $50/month cap under a Trump administration agreement with manufacturers. For clients on these medications, the savings can exceed $1,000 annually relative to prior costs, though the IRMAA tier surcharge on premiums can easily offset that gain for higher-income retirees.

What’s Different in 2027: Why Planning Starts Now

The 2027 IRMAA brackets — which will be based on 2025 MAGI — will not be announced until late 2026. However, CMS’s historical pattern of modest inflation-indexing on bracket thresholds means the $109,000 single / $218,000 MFJ first-tier entry points are unlikely to shift dramatically.

What may change: if Congress acts on proposed Medicare means-testing expansions, the surcharge structure could steepen further. Several proposals circulating in the Senate Finance Committee would add a sixth IRMAA tier above $750,000 (MFJ) with a Part B premium approaching $700/month. Advisors working with ultra-high-net-worth clients should monitor this legislative track.

For a deeper retirement income planning framework — including the safe withdrawal rate calculus and how healthcare costs interact with distribution sequencing — the Bengen 4.7% rule analysis published here provides a useful companion read.

Questions to Bring to Your Next Client Meeting

1. What was your client’s 2024 MAGI, and at what IRMAA tier does that place them for 2026? Have you already begun modeling which income-management actions in 2026 would reduce their 2028 surcharge exposure?

1. For clients over 70½ with traditional IRAs: what portion of their annual charitable giving could be redirected through QCDs, and have you calculated the net tax and IRMAA savings of doing so vs. the current approach?

1. If your client had an income spike in 2024 due to a qualifying life event — business sale, job loss, divorce — have you reviewed whether a Form SSA-44 appeal to the Social Security Administration is appropriate to reduce their current IRMAA tier?

Sources: Centers for Medicare & Medicaid Services — 2026 Medicare Parts A & B Premiums and Deductibles (CMS fact sheet); Kiplinger — Medicare Premiums 2026: IRMAA Brackets and Surcharges; Greenbush Financial Group — IRMAA 2026 Advisor Guide; Morningstar — Retirement Planning Research 2025; Social Security Administration Form SSA-44; The Motley Fool — Medicare Premium / COLA Analysis April 2026.